Drug Trial Radar · NCT04378075
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy
Last checked: Nov 20, 2026Latest source record: Mar 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
68
Actual
Start
Sep 28, 2020
Primary completion
Mar 18, 2023
Study completion Dec 27, 2023
Sponsor
- Lead sponsor
- PTC TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- May 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a parallel-arm, double-blind, placebo-controlled study with a screening phase that includes a 28-day run-in phase to establish baseline seizure frequency, followed by a 24-week, randomized, placebo-controlled phase. After completion of the randomized, placebo-controlled phase, participants may enter a 48-week, long-term, extension phase during which they will receive open-label treatment with vatiquinone.
Conditions
- Mitochondrial Diseases
- Drug Resistant Epilepsy
- Leigh Disease
- Leigh Syndrome
- Mitochondrial Encephalopathy (MELAS)
- Pontocerebellar Hypoplasia Type 6 (PCH6)
- Alpers Disease
- Alpers Syndrome
Interventions
VatiquinoneDrug
Vatiquinone will be administered per the treatment arm description.
PlaceboOther
Vatiquinone-matching placebo will be administered per the treatment arm description
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline to Week 24 in the Number of Observable Motor Seizures Per 28 Days During the Double-blind PeriodTime frame: Baseline to Week 24
Locations
27 sites in 9 countries. Site status is shown where the registry gives one.
University of California
San Diego, California
Stanford University
Stanford, California
Yale School of Medicine
New Haven, Connecticut
Children's National Medical Center - Department Of Neurology
Washington D.C., District of Columbia
John Hopkins Medicine
Baltimore, Maryland
Pediatric Genetics Clinic (Main MGH Hospital)
Boston, Massachusetts
Boston Children Hospital
Boston, Massachusetts
Children's of Minnesota
Minneapolis, Minnesota
Akron Children's Hospital
Akron, Ohio
Baylor College of Medicine
Houston, Texas
University of Texas Health Science
Houston, Texas
Seattle Children's hospital
Seattle, Washington
Alberta Children's Hospital, University of Calgary
Calgary, Canada
CHU d'Angers - Service de génétique
Angers, France
CHU de Montpellier - Hôpital Gui de Chauliac - Département de neuropédiatrie
Montpellier, France
A.P.H.P - Hôpital Necker-Enfants Malades - Service de Neurologie pédiatrique
Paris, France
CHU de Strasbourg - Hôpital de Hautepierre - Service de Neuropédiatrie
Strasbourg, France
UOC Neuropsichiatria Infantile, Istituto Neurologico Carlo Besta-Fondazione IRCCS
Milan, Italy
U.O.C. Malattie Muscolari e Neurodegenerative, Dipartimento di Scienze Neurologiche e Psichiatriche, Ospedale Pediatrico Bambino Gesù
Roma, Italy
PTC Clinical Site
Multiple Locations, Japan
Instytut Pomnik-Centrum Zdrowia Dziecka, Centrum Wsparacia Pediatrycznych Badań Klinicznych
Warsaw, Poland
Hospital Sant Joan de Déu
Barcelona, Spain
Hospital Ruber Internacional, Neurology Department, Epilepsy Program
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Karolinska University hospital, Astrid Lindgrens Children Hospital
Stockholm, Sweden
Great Ormond Street Hospital for Children NHS Foundation Trust
London, United Kingdom
The Newcastle Upon Tyne Hospitals NHS Foundation Trust
Newcastle upon Tyne, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.